New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - prasugrel hydrochloride 5.49mg - film coated tablet - 5 mg - active: prasugrel hydrochloride 5.49mg excipient: croscarmellose sodium glycerol hypromellose iron oxide yellow lactose magnesium stearate mannitol microcrystalline cellulose purified talc titanium dioxide - effient, co-administered with aspirin, is indicated for the prevention of atherothrombotic events (myocardial infarction, stroke and cardiovascular death) in patients with acute coronary syndromes (moderate to high risk unstable angina (ua), non st-segment elevation myocardial infarction (nstemi) or st-segment elevation myocardial infarction (stemi)) who are to undergo percutaneous coronary intervention (pci).

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - dapagliflozin propanediol monohydrate 12.3mg equivalent to dapaglifozin 10mg;   - film coated tablet - 10 mg - active: dapagliflozin propanediol monohydrate 12.3mg equivalent to dapaglifozin 10mg   excipient: colloidal silicon dioxide crospovidone opadry ii yellow lactose magnesium stearate microcrystalline cellulose - monotherapy forxiga is indicated in adults with type 2 diabetes mellitus as monotherapy as an adjunct to diet and exercise in patients for whom metformin is otherwise indicated but was not tolerated. initial combination forxiga is indicated in adults with type 2 diabetes mellitus as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycaemic control when diet and exercise have failed to provide adequate glycaemic control and there are poor prospects for response to metformin monotherapy. add-on combination forxiga is indicated in adult patients with type 2 diabetes mellitus in combination with other anti-hyperglycaemic agents to improve glycaemic control, when these together with diet and exercise do not provide adequate glycaemic control. prevention of hospitalisation for heart failure forxiga is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalisation for heart. prevention of new or worsening nephropathy forxiga is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease for the prevention of new or worsening nephropathy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - epirubicin hydrochloride 2 mg/ml;   - solution for injection - 2 mg/ml - active: epirubicin hydrochloride 2 mg/ml   excipient: hydrochloric acid sodium chloride water for injection - epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, and superficial bladder cancer (tis, ta). in bladder cancer, epirubicin hydrochloride is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - finasteride 1mg;   - film coated tablet - 1 mg - active: finasteride 1mg   excipient: lauroyl macrogolglycerides lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink pregelatinised maize starch sodium starch glycolate - · finaccord tablets are indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss. · finaccord tablets are not indicated for use in women or children. finaccord tablets are not effective in postmenopausal women with androgenetic alopecia.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - abacavir sulfate 702mg equivalent to abacavir 600 mg;  ;  ; lamivudine 300mg;   - film coated tablet - 600mg/300mg - active: abacavir sulfate 702mg equivalent to abacavir 600 mg     lamivudine 300mg   excipient: magnesium stearate microcrystalline cellulose opadry orange ys-1-13065a sodium starch glycolate - kivexa is a combination of two nucleoside analogues (abacavir and lamivudine). it is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - lamotrigine 100mg - chewable/dispersible tablet - 100 mg - active: lamotrigine 100mg excipient: calcium carbonate colloidal silicon dioxide crospovidone maize starch microcrystalline cellulose purified talc ribes nigrum saccharin sodium sodium stearyl fumarate sorbitol

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - lamotrigine 200mg - chewable/dispersible tablet - 200 mg - active: lamotrigine 200mg excipient: calcium carbonate colloidal silicon dioxide crospovidone maize starch microcrystalline cellulose purified talc ribes nigrum saccharin sodium sodium stearyl fumarate sorbitol

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - lamotrigine 25mg - chewable/dispersible tablet - 25 mg - active: lamotrigine 25mg excipient: calcium carbonate colloidal silicon dioxide crospovidone maize starch microcrystalline cellulose purified talc ribes nigrum saccharin sodium sodium stearyl fumarate sorbitol

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - lamotrigine 50mg - chewable/dispersible tablet - 50 mg - active: lamotrigine 50mg excipient: calcium carbonate colloidal silicon dioxide crospovidone maize starch microcrystalline cellulose purified talc ribes nigrum saccharin sodium sodium stearyl fumarate sorbitol

New Zealand - English - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - domperidone 10mg;   - tablet - 10 mg - active: domperidone 10mg   excipient: cottonseed oil, hydrogenated hypromellose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone purified water   sodium laurilsulfate   starch - adults and adolescents weighing 35kg or more: symptomatic treatment of the dyspeptic symptom complex that may be associated with delayed gastic emptying such as epigastric sense of fullness, abdominal distension or swelling, or epigastric pain or discomfort.